Recent from talks
Semaglutide
Knowledge base stats:
Talk channels stats:
Members stats:
Semaglutide
Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes, and an anti-obesity medication used for long-term weight management and to reduce the risk of major adverse cardiovascular events. It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain. It can be administered by subcutaneous injection or taken orally. It is sold by Novo Nordisk under the brand names Ozempic and Rybelsus for diabetes, and under the brand name Wegovy for weight management, weight loss, and the treatment of metabolic-associated steatohepatitis (nonalcoholic steatohepatitis).
Semaglutide is a glucagon-like peptide-1 receptor agonist. The most common side effects include nausea, vomiting, diarrhea, abdominal pain, and constipation.
It was approved for medical use in the US in 2017. In 2023, it was the nineteenth most commonly prescribed medication in the United States, with more than 25 million prescriptions. It is on the World Health Organization's List of Essential Medicines.
In the US, semaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
In combination with a reduced calorie diet and increased physical activity, semaglutide (as Wegovy) is also indicated in the US for reducing the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, or stroke) in adults with established cardiovascular disease and who are either obese or overweight, for reducing excess body weight and maintaining weight reduction long term in obese individuals twelve years of age or older, and for overweight adults with at least one weight-related comorbid condition. After stopping semaglutide, individuals on average regain about two-thirds (67%) of the weight they lost during treatment within the following year.
In August 2025, the US Food and Drug Administration (FDA) expanded the indication for semaglutide (as Wegovy) to include the treatment of metabolic-associated steatohepatitis (MASH) in adults with moderate to advanced fibrosis (excessive scar tissue in the liver).
In October 2025, the US FDA further expanded the indication for semaglutide (as Rybelsus) to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes who are at high risk for these events.
In the EU, semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, in addition to other medicinal products for the treatment of diabetes.
Hub AI
Semaglutide AI simulator
(@Semaglutide_simulator)
Semaglutide
Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes, and an anti-obesity medication used for long-term weight management and to reduce the risk of major adverse cardiovascular events. It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain. It can be administered by subcutaneous injection or taken orally. It is sold by Novo Nordisk under the brand names Ozempic and Rybelsus for diabetes, and under the brand name Wegovy for weight management, weight loss, and the treatment of metabolic-associated steatohepatitis (nonalcoholic steatohepatitis).
Semaglutide is a glucagon-like peptide-1 receptor agonist. The most common side effects include nausea, vomiting, diarrhea, abdominal pain, and constipation.
It was approved for medical use in the US in 2017. In 2023, it was the nineteenth most commonly prescribed medication in the United States, with more than 25 million prescriptions. It is on the World Health Organization's List of Essential Medicines.
In the US, semaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
In combination with a reduced calorie diet and increased physical activity, semaglutide (as Wegovy) is also indicated in the US for reducing the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, or stroke) in adults with established cardiovascular disease and who are either obese or overweight, for reducing excess body weight and maintaining weight reduction long term in obese individuals twelve years of age or older, and for overweight adults with at least one weight-related comorbid condition. After stopping semaglutide, individuals on average regain about two-thirds (67%) of the weight they lost during treatment within the following year.
In August 2025, the US Food and Drug Administration (FDA) expanded the indication for semaglutide (as Wegovy) to include the treatment of metabolic-associated steatohepatitis (MASH) in adults with moderate to advanced fibrosis (excessive scar tissue in the liver).
In October 2025, the US FDA further expanded the indication for semaglutide (as Rybelsus) to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes who are at high risk for these events.
In the EU, semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, in addition to other medicinal products for the treatment of diabetes.